1.235
price up icon4.66%   0.055
after-market 시간 외 거래: 1.24 0.005 +0.40%
loading
전일 마감가:
$1.18
열려 있는:
$1.25
하루 거래량:
96,726
Relative Volume:
0.70
시가총액:
$13.23M
수익:
-
순이익/손실:
$-9.70M
주가수익비율:
-1.1227
EPS:
-1.1
순현금흐름:
$-8.57M
1주 성능:
-17.67%
1개월 성능:
-28.20%
6개월 성능:
-55.49%
1년 성능:
-72.37%
1일 변동 폭
Value
$1.1597
$1.30
1주일 범위
Value
$1.13
$1.99
52주 변동 폭
Value
$1.13
$5.99

마커 테라퓨틱스 Stock (MRKR) Company Profile

Name
명칭
Marker Therapeutics Inc
Name
전화
(713) 400-6400
Name
주소
2450 HOLCOMBE BLVD, HOUSTON, TX
Name
직원
8
Name
트위터
@MRKRTherapeutic
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
MRKR's Discussions on Twitter

MRKR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
MRKR
Marker Therapeutics Inc
1.235 13.23M 0 -9.70M -8.57M -1.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
504.77 129.62B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
666.87 72.91B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
604.96 36.76B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.76 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
259.19 27.86B 3.32B -860.46M -1.04B -8.32

마커 테라퓨틱스 Stock (MRKR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-05 개시 Canaccord Genuity Buy
2021-03-25 개시 Piper Sandler Overweight
2021-03-19 개시 Cantor Fitzgerald Overweight
2020-05-12 다운그레이드 Piper Sandler Overweight → Neutral
2019-05-30 개시 ROTH Capital Buy
2019-03-01 개시 Janney Buy
2018-12-03 업그레이드 Piper Jaffray Neutral → Overweight
모두보기

마커 테라퓨틱스 주식(MRKR)의 최신 뉴스

pulisher
Mar 14, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Mar 14, 2025
pulisher
Mar 11, 2025

MRKR stock touches 52-week low at $1.35 amid market challenges - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

MRKR stock touches 52-week low at $1.35 amid market challenges By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 07, 2025

Canaccord Genuity Group Initiates Coverage on Marker Therapeutics (NASDAQ:MRKR) - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews

Mar 06, 2025
pulisher
Mar 05, 2025

This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga India

Mar 05, 2025
pulisher
Mar 05, 2025

Canaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy Recommendation - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Marker Therapeutics initiated with a Buy at Canaccord - TipRanks

Mar 05, 2025
pulisher
Mar 03, 2025

MRKR stock touches 52-week low at $1.45 amid market challenges - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

MRKR stock touches 52-week low at $1.45 amid market challenges By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Feb 25, 2025

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Will Marker Therapeutics Reveal New Clinical Data at Upcoming Cell Therapy Conference? - StockTitan

Feb 25, 2025
pulisher
Feb 24, 2025

MRKR stock touches 52-week low at $1.48 amid market challenges - Investing.com India

Feb 24, 2025
pulisher
Feb 24, 2025

MRKR stock touches 52-week low at $1.48 amid market challenges By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 20, 2025

Marker Therapeutics grants stock options to CEO and directors By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 20, 2025

Marker Therapeutics grants stock options to CEO and directors - Investing.com India

Feb 20, 2025
pulisher
Feb 15, 2025

Marker Therapeutics (MRKR) Stock Price, News & Analysis - MarketBeat

Feb 15, 2025
pulisher
Feb 14, 2025

Analysts Offer Predictions for MRKR FY2024 Earnings - Defense World

Feb 14, 2025
pulisher
Feb 13, 2025

Marker Therapeutics (NASDAQ:MRKR) Upgraded at Brookline Capital Management - Defense World

Feb 13, 2025
pulisher
Feb 12, 2025

Brookline Capital sets $4 target on Marker Therapeutics stock - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

MRKR stock touches 52-week low at $1.61 amid market challenges - Investing.com Nigeria

Feb 12, 2025
pulisher
Feb 11, 2025

Brookline Capital sets $4 target on Marker Therapeutics stock By Investing.com - Investing.com Australia

Feb 11, 2025
pulisher
Feb 11, 2025

H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

MRKR stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 2.8% – Here’s Why - Defense World

Feb 11, 2025
pulisher
Feb 07, 2025

Cytokinetics draws new Buy from Citi on aficamten potential - MSN

Feb 07, 2025
pulisher
Feb 05, 2025

Biotech Analysis Central Model 10+ Portfolio Pick#16 Marker Therapeutics; MT-601 Lymphoma Data 2nd Half Of 2024, Study Initiation Of OTS MT-401 For AML And Catalysts (NASDAQ:MRKR) - Seeking Alpha

Feb 05, 2025
pulisher
Feb 03, 2025

Marker Therapeutics Announces Board Resignation - MSN

Feb 03, 2025
pulisher
Feb 01, 2025

MRKR stock touches 52-week low at $1.8 amid market challenges - MSN

Feb 01, 2025
pulisher
Jan 30, 2025

Marker Therapeutics Announces Board Resignation By Investing.com - Investing.com Nigeria

Jan 30, 2025
pulisher
Jan 29, 2025

Marker Therapeutics pops on receiving $9.5M grant to advance lead asset - MSN

Jan 29, 2025
pulisher
Jan 24, 2025

Hematopoietic Stem Cell Transplantation Market: Soaring - openPR

Jan 24, 2025
pulisher
Jan 22, 2025

MRKR stock touches 52-week low at $2.4 amid challenging year - MSN

Jan 22, 2025
pulisher
Jan 21, 2025

MRKR stock touches 52-week low at $2.4 amid challenging year By Investing.com - Investing.com South Africa

Jan 21, 2025
pulisher
Jan 18, 2025

Marker Therapeutics (NASDAQ:MRKR) Shares Down 7.5% – What’s Next? - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

SEC Form 424B3 filed by Marker Therapeutics Inc. - Quantisnow

Jan 17, 2025
pulisher
Jan 14, 2025

BostonGene Evaluates Novel Therapies and Immune System Profiling as a Marker of Response in Patients with Gastrointestinal Cancers - Business Wire

Jan 14, 2025

마커 테라퓨틱스 (MRKR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$307.24
price up icon 0.61%
$76.55
price up icon 1.97%
$32.77
price up icon 0.28%
$20.79
price up icon 8.34%
$99.47
price up icon 2.06%
biotechnology ONC
$259.19
price up icon 1.81%
자본화:     |  볼륨(24시간):